July 31, 2001
Product Release:Hornel Tablets Active Vitamin D3 Derivative
Taisho Pharmaceutical Co. Ltd. (President: Akira Uehara) began sales on August 1 of Hornel tablets, an active vitamin D3 derivative that is generically known as falecalcitriol. Taisho received manufacturing approval on April 4, 2001, and finalized the retail price on June 1.
Hornel tablets can relieve such adverse events as hypocalcemia, rickets,osteomalacia,and secondary hyperparathyroidism. For the first time, the tablets can be administered orally to effectively control the parathyroid hormone in dialysis patients and maintain an optimal range of serum calcium concentration.
Falecalcitriol was developed in the 1980s through the joint research activities of the Tokyo Institute of Technology and the Tokyo University of Pharmacy and Life Science. Active vitamin D3 enables a highly potent and long-lasting product in a small dosage because it converts all the H26 and H27 molecules to fluoride, and limits the effects of nonactive bodies (Hydroxide 24) through metabolism. It also fosters the main metabolites (Hydroxide 23)
Taisho and Sumitomo Pharmaceuticals, Co., Ltd. jointly licensed Falecalcitriol from the Wisconsin Alumni Research Foundation (WARF) in 1984 and began developing it for the Japanese market. Sumitomo has commissioned Kissei Pharmaceutical to market its product, which will be released August 1, as Fulstan tablets.